Company details

HEADCOUNT

25-99

ORG TYPE

Startup

SECTOR

Healthcare & Life Sciences

WEBSITE

https://www.variantbio.com

About the company

Variant Bio is a Seattle-based biotech working on genomic drug discovery, with a stated focus on learning from genetic “outliers” and partnering with diverse communities to generate insights for new therapies. Public materials emphasise ethical genomics, benefit sharing, and cross-disciplinary teams spanning genetics, therapeutics, anthropology, and ethics. Variant Bio currently shows no open roles on the company careers page or Greenhouse board, which makes the early-career picture harder to judge from live listings. The most concrete early-career pathway the company publishes is a paid, remote fellowship tied to partnership-building and genomic analysis.

Locations and presence

Variant Bio lists Seattle, Washington as headquarters, with some roles and the fellowship framed as compatible with remote participation. The company’s public-facing footprint is primarily US-based, with global partner-community work referenced through the fellowship and genomics collaboration model.

Palpable Score

52.3

/ 100

Variant Bio has one strong early-career signal in a paid fellowship with real project ownership, plus unusually clear benefits language for a small biotech. The score is held back by the lack of current openings and limited public evidence on interview structure, onboarding mechanics, and repeatable junior progression.

Pillar 1: Early-career access

Score

8.0

/ 20

The company currently lists no open positions on the main careers page, which removes the most straightforward entry point for graduates.
Variant Bio publishes the Standley Fellowship as an ongoing opportunity, which creates a practical early-career route even when the job board is quiet.
The company does not show a recurring pattern of “0–3 years” roles or internships beyond the fellowship, so entry-level access looks occasional rather than dependable.

‍

Pillar 2: Hiring fairness and transparency

Score

10.0

/ 20

The company uses Greenhouse for applications, which supports a consistent, trackable application route when roles are open.
Variant Bio has candidate reports describing multi-round interviews but also disappointment around process expectations and closure, which is a risk for early-career confidence.
The company does not publish a standard interview loop, timelines, or assessment expectations on the careers page, so transparency depends on the team and role.

‍

Pillar 3: Learning and support

Score

11.0

/ 20

The company frames the Standley Fellowship as joining an “exceptional network of scientists” with a voice in partner dialogue, which is a concrete mentoring and exposure signal.
Variant Bio describes interdisciplinary collaboration across science, anthropology, and business, which can be a strong learning environment for early-career hires when supported well.
The company does not publish verifiable onboarding and feedback mechanics like buddying, review cadence, or protected learning time in role materials.

‍

Pillar 4: Pay fairness and stability

Score

15.3

/ 20

The company publicly states that Variant Bio offers competitive salary and equity, employer 401(k) contributions, and company-paid professional development opportunities.
Variant Bio also states that medical, dental, and vision premiums are paid 100% for employees, which is a standout stability signal for a small biotech.
The company does not consistently publish salary ranges in public postings, which caps confidence on pay fairness for specific early-career roles.

‍

Pillar 5: Early-career outcomes

Score

8.0

/ 20

The company does not publish outcome metrics like retention over 12–24 months, promotion timelines, or internship-to-offer conversion rates.
Variant Bio’s fellowship page includes an explicit example of a Fellow later joining the Partnerships Team, which is a concrete (but small-sample) progression signal.
The company has limited independent early-career outcome evidence in public sources, so it is not possible to summarise repeatable junior-to-mid growth patterns.

‍